From: Tryptophan catabolism and immune activation in primary and chronic HIV infection
 | Primary HIV infection N = 14 | Early presenters N = 24 | Late presenters N = 19 | Healthy controls N = 16 | P |
---|---|---|---|---|---|
Gender, males/females, (% males) | 13/1 (92.9) | 22/2 (91.7) | 18/1 (94.7) | 15/1 (93.8) | .948 |
Age, years, mean (SD) | 46 (8.9) | 45 (8.2) | 47 (10.1) | 43 (9.4) | .529 |
CD8+ at baseline, cells/μL, mean (SD) | 1238.6 (659.8) | 1123.5 (547.5) | 820.1 (556.0) | 915.7 (409.7) | .116 |
CD4+ at baseline, cells/μL, mean (SD) | 577.8 (228.5) a,d | 527.9 (111.2)c,f | 72.7 (62.7)a,c,e | 1144.0 (329.0)d,e,f | < .001 |
CD4/CD8 at baseline, mean (SD) | 0.6 (0.4)a,d | 0.6 (0.2)c,f | 0.1 (0.1)a,c,e | 1.4 (0.5)d,e,f | < .001 |
Co-infection with chronic HBV/HCV, N | 0/1 | 1/0 | 0/2 | 0/0 | NA |
HIV RNA at baseline, mean (SD) | 2,413,322 (4,119,479)a,b | 97,328 (253,967)b,c | 486,483 (524,072)a,c | NA | < .001 |
AIDS defining events, N | 0 | 0 | 1 | NA | NA |
KTratio at baseline, mean (SD) | 46.8 (20.3)a,b,d | 34.8 (10.6)b,c,f | 74.5 (48.1)a,c,e | 20.9 (3.7)d,e,f | < .001 |
CD8Â +Â CD38Â +Â HLA-DR+, % cells, mean (SD) | 44.7 (20.3) a,b,d | 22.0 (13.4)b,c,f | 25.5 (21.3)a,c,e | 1.3 (0.8)d,e,f | < .001 |
CD4Â +Â CD38Â +Â HLA-DR+, % cells, mean (SD) | 5.5 (4.1)a,d | 3.5 (3.0)c,f | 15.5 (15.4)a,c,e | 0.8 (0.6)d,e,f | < .001 |